SYRE · Spyre Therapeutics, Inc. · Debt
$99.23
+0.18 (+0.18%)
At close · Oct 28
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$8.72B
Shares
88.17M
Volume · Oct 28
722.56K
Avg daily vol (3M)
1.21M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current finance lease liabilities | 2023-12-31 | USD 0 | 10-K/A filed 2024-11-18 |
| Current operating lease liabilities | 2023-12-31 | USD 0 | 10-K/A filed 2024-11-18 |
| Noncurrent operating lease liabilities | 2023-12-31 | USD 0 | 10-K/A filed 2024-11-18 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1636282
CUSIP
00773J202
13F (30d)
27 filings
27 filers
Visit website
Investor relations